PMC:7242013 / 5441-5623 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"181","span":{"begin":132,"end":140},"obj":"Species"},{"id":"223","span":{"begin":72,"end":110},"obj":"Disease"},{"id":"224","span":{"begin":146,"end":151},"obj":"Disease"}],"attributes":[{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"Tax:9606"},{"id":"A223","pred":"tao:has_database_id","subj":"223","obj":"MESH:D006509"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"enerally safe)\nLimit use of nonsteroidal anti‐inflammatory drugs\nManage hepatitis B; hepatitis C Continue HBV and HCV treatment of patients with COVID‐19\nProceed with HBV and HCV tr"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T75","span":{"begin":72,"end":83},"obj":"Disease"},{"id":"T76","span":{"begin":72,"end":81},"obj":"Disease"},{"id":"T77","span":{"begin":85,"end":96},"obj":"Disease"},{"id":"T78","span":{"begin":85,"end":94},"obj":"Disease"},{"id":"T79","span":{"begin":146,"end":154},"obj":"Disease"}],"attributes":[{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0005344"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0005231"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"enerally safe)\nLimit use of nonsteroidal anti‐inflammatory drugs\nManage hepatitis B; hepatitis C Continue HBV and HCV treatment of patients with COVID‐19\nProceed with HBV and HCV tr"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T60","span":{"begin":82,"end":83},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"enerally safe)\nLimit use of nonsteroidal anti‐inflammatory drugs\nManage hepatitis B; hepatitis C Continue HBV and HCV treatment of patients with COVID‐19\nProceed with HBV and HCV tr"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T24","span":{"begin":41,"end":64},"obj":"Chemical"},{"id":"T25","span":{"begin":59,"end":64},"obj":"Chemical"},{"id":"T26","span":{"begin":65,"end":71},"obj":"Chemical"}],"attributes":[{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_35472"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_81767"}],"text":"enerally safe)\nLimit use of nonsteroidal anti‐inflammatory drugs\nManage hepatitis B; hepatitis C Continue HBV and HCV treatment of patients with COVID‐19\nProceed with HBV and HCV tr"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T73","span":{"begin":15,"end":64},"obj":"Sentence"},{"id":"T74","span":{"begin":65,"end":154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"enerally safe)\nLimit use of nonsteroidal anti‐inflammatory drugs\nManage hepatitis B; hepatitis C Continue HBV and HCV treatment of patients with COVID‐19\nProceed with HBV and HCV tr"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T18","span":{"begin":72,"end":81},"obj":"Phenotype"},{"id":"T19","span":{"begin":85,"end":94},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0012115"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"enerally safe)\nLimit use of nonsteroidal anti‐inflammatory drugs\nManage hepatitis B; hepatitis C Continue HBV and HCV treatment of patients with COVID‐19\nProceed with HBV and HCV tr"}